

PUBLICATIONS: Philippa Musoke

1. **Mudido P**, Marshall G et al. Disseminated Herpes Simplex Virus infection during Pregnancy. A case report. *J Reprod Med* 1993;38:964-968.
2. Lederman M M, Georges D, **Mudido P**, et al. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. *J AIDS* 1994;7:727-733.
3. Marshall G S, **Mudido P**, Rabalais G, Adams G. Organism Isolation and Serum Bactericidal Titers in Oral Antibiotic Therapy of Pediatric Osteomyelitis. *South Med J*. 1996; 98: 1 68-70.
4. **Mudido P**, Georges D, Dorazio D, Yen- Lieberman, et al. Human immunodeficiency virus type 1 activation after blood transfusion. *Transfusion* 1996;36:860-865.
5. Kalyesubula I K, **Musoke-Mudido P**, Bagenda D, Marum L, et al. Malaria in a cohort of HIV infected children. *Pediatric Infect Dis*.1997;16:876 - 81.
6. Bruce J Dezube, Michael M Lederman, Beryl Chapman, Daniel L. Georges, Alex L Dogon, **Philippa Mudido** et al. The effect of Tenidap on Cytokines, Acute-Phase Proteins, and Virus Load in Human Immunodeficiency Virus (HIV) - Infected Patients: Correlation between Plasma HIV-1 RNA and Proinflammatory Cytokine Levels. *J I D* 1997; 176:807- 810.
7. Ann Maria Mandalakas, Laura Guay, **Philippa Musoke**, et al. Human Immunodeficiency Virus Status and Delayed-Type Hypersensitivity Skin Testing in Ugandan Children. *Paed* 1999; 103:2
8. **Musoke P**, Guay L, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of Nevirapine in HIV-1 Infected pregnant Ugandan women and their infants. *AIDS* 1999;13:4:479 – 485.
9. **Musoke Mudido P**, Guwattude D, Nakakeeto MN et al. The effects of BCG at birth on tuberculin skin test reactivity in Ugandan Children. *Int J TB & Lung Ds* 1999;3:891-895.
10. Laura A Guay, **Philippa Musoke**, Thomas Fleming, et al. Intrapartum and neonatal single- dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. *Lancet* 1999; 354:795-802.
11. Elliot Marseille, James G Kahn, Francis Mmiro, Laura Guay, **Philippa Musoke** et al. Cost effectiveness of single dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. *Lancet* 1999; 354: 803 - 809.
12. **Philippa M Musoke** & Francis Mmiro. Prevention of HIV Mother to Child Transmission: A review. *AIDS Rev* 2000;2:263-270.
13. Jackson JB, Becker-Pergola G, Guay LA, **Musoke P**, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. *AIDS*. 2000 Jul 28;14(11):F111-5.
14. Marseille E, Kahn JG, Mmiro F, Guay L, **Musoke P**, Fowler MG, Jackson JB. The cost effectiveness of a single-dose nevirapine regimen to mother and infant to reduce vertical HIV-1 transmission in sub-Saharan Africa. *Ann N Y Acad Sci*. 2000 Nov; 918:53-6.

15. Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, **Musoke P**, Mmiro F, Jackson JB. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV network for prevention trials 012 study). *J Infect Dis.* 2001; 184 (7): 914-7.
16. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, **Musoke P**, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). *AIDS.* 2001;15 (15):1951-7.
17. Guay LA, **Musoke P**, Hom DL, Nakabiito C, Bagenda D, Fletcher CV, Marum LH, Fowler MG, Falksveden LG, Wahren B, Kataaha P, Wigzell H, Mmiro FA, Jackson JB. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. *AIDS.* 2002 ;16 (10):1391-400.
18. Eshleman SH, Guay LA, Fleming T, Mwatha A, Mracna M, Becker-Pergola G, **Musoke P**, Mmiro F, Jackson JB. Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012). *J Acquir Immune Defic Syndr.* 2002; 31(3):327-330.
19. Jackson JB, **Musoke P**, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Mwatha A, Emel L, Duefield C, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. *Lancet.* 2003;362 (9387):859-68
20. Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, **Musoke P**, Mmiro F, Jackson JB. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). *J Acquir Immune Defic Syndr.* 2004; 35(2):126-30.
21. Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, **Musoke P**, Mmiro F, Jackson JB. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012. *AIDS Res Hum Retroviruses.* 2004; 20(6):595-9.
22. Bakeera-Kitaka S, **Musoke P**, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. *Ann Trop Paediatr* 2004;(3): 227 -35.
23. Cressey TR, Jourdain G, Lallemand MJ, Kunkeaw S, Jackson J B, **Musoke P**, Capparelli E, Mirochnick M. Persistence of Nevirapine Exposure During the Postpartum Period After Intrapartum Single-Dose Nevirapine in Addition to Zidovudine Prophylaxis for the Prevention of Mother-to-Child Transmission of HIV-1 *J Acquir Immune Defic Syndr.* 2005; 38(3):283-8.
24. R. Iriso, **PM Mudido**, C. Karamagi, C Whalen. The diagnosis of childhood TB in an HIV endemic setting and the use of induced sputum. *Int J Tuberc Lung Dis.* 2005, 9 (7):716 - 726
25. SH Eshelman, LA Guay, J Wang, A Mwatha, ER Brown, **P. Musoke** et al. Distinct Patterns of Emergence and Fading of K103N and Y 181C in women with subtype A

- vs D After Single-Dose Nevirapine HIVNET 012. *J Acquir Immune Defic Syndr* 2005; 40 : 24 -29.
26. SH Eshelman, LA Guay, A Mwatha, ER Brown, **P. Musoke** et al. Comparison of Mother-to-Child Transmission Rates in Ugandan Women with subtype A versus D HIV-1 Who received single-dose Nevirapine prophylaxis. *J Acquir Immune Defic Syndr*. 2005 Aug 15; 39 : 593 – 597.
 27. Dana Jones, Neil Parkin, Sarah Hudelson, Laura Guay, **Philippa Musoke** et al. Genetic Linkage of Nevirapine Resistance Mutations in HIV Type 1 Seven Days after Single-Dose Nevirapine. *AIDS Res and Hum Retrovir*. 2005, 21;(4):319 -324.
 28. Susan H Eshelman, Donald R Hoover, Shu Chen, Sarah E Hudelson, Laura A Guay, Anthony Mwatha, Susan A Fiscus, Francis Mmiro, **Philippa Musoke** et al. Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with subtypes A and D, after the administration of single-dose NVP. *JID* 2005;192: 30-36.
 29. Eshelman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, **Musoke P**, et al. Resistance after single dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. *AIDS* 2005 19(18):2167-9.
 30. Tamara Flys, Dwight V Nissley, Cassidy W Claasen, Dana Jones, Chanjuan Shi, Laura A Guay, **Philippa Musoke** et al. Sensitive Drug-Resistant Assays Reveal Long Term Persistence of HIV-1 variants with the K103N Nevirapine resistance Mutations in some Women and Infants after administration of single-dose NVP: HIVNET 012. *J Infect Dis* 2005;192: 24-29.
 31. Eshelman SH, Church JD, Chen S, Guay LA, Mwatha A Fiscus SA, Mmiro F, **Musoke P**, et al. Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. *JAIDS* 42(4):518-521.
 32. Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, **Musoke P** et al. Quantitative analysis of HIV-1 variants with K103N resistance mutation after single dose nevirapine in women with HIV-1 subtypes A, C, and D. *JAIDS* 2006 15;42 (5):610-613.
 33. Jackson JB, Parson T, **Musoke P**, et al. Association of cord blood nevirapine concentration with reported timing of dose and HIV-transmission. *AIDS* 2006.9;20(2):217-222.
 34. Babirekere-Iriso E, **Musoke P**, Kekitiinwa A. Bacteraemia in severely malnourished children in HIV-endemic setting. *Ann Trop Paediatr* 2006 26(4):319-28.
 35. Tamara S. Flys, Deborah Donnell, Anthony Mwatha, Clemensia Nakabiito, **Philippa Musoke**, Francis Mmiro, J. Brooks Jackson, Laura A. Guay, and Susan H. Eshleman. Persistence of K103N-containing HIV-1 variants after single dose nevirapine for prevention of HIV-1 mother-to-child transmission. *J. Infect Dis*. 2007;195(5):711-715
 36. Huang W, Eshelman SH, Toma J, Frnsen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell, Mmiro F, **Musoke P** et al. Co-receptors Tropism in subtype D HIV-1: High prevalence of CXCR4 Tropism and heterogenous composition of viral populations. *J Virol*. 2007 May 16.
 37. Church JD, Hudelson SE, Guay LA, Chen S, Hoover DR, Parkin N, Fiscus SA, Mmiro F, **Musoke P**, Kumwenda N, Jackson JB, Taha TE, and Eshleman SH. HIV-1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug

- naïve African women with subtypes A, C, and D. *AIDS Res Human Retroviruses*. 2007; 23:764-768.
38. Chou VB, Omer SB, Hussain H, Mugasha C, Musisi M, Mmiro F, **Musoke P**, Jackson JB, Guay LA. The costs associated with adverse event procedures for an international HIV clinical trial determined by activity-based costing. *J Acquir Immune Defic Syndr*. 2007 Dec 1;46(4):426-32.
 39. Owens S, Abdel-Rahman IE, Balyejusa S, **Musoke P**, Cooke RP, Parry CM, Coulter JB. Nasopharyngeal aspiration for diagnosis of pulmonary tuberculosis. *Arch Dis Child*. 2007 Aug;92(8):693-6.
 40. Bliss SJ, O'Brien KL, Janoff EN, Cotton MF, **Musoke P**, Coovadia H, Levine OS. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. *Lancet Infect Dis* 2008 Jan;8(1):67-80.
 41. **Musoke PM**, Young A, Owor MA, et al Total Lymphocyte Count: Not a surrogate marker for risk of death in HIV-1 infected Ugandan children. *J Acquir Immune Defic Syndr*. 2008;49:171-178.
 42. Singh KK, Hughes MD, Chen J, Phiri K, Rousseau C, Kuhn L, Coutsooudis A, Jackson JB, Guay LA, **Musoke P**, Mmiro F, Semba RD, Spector SA. Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals. *J Acquir Immune Defic Syndr*. 2008;49(3):259-65.
 43. Kekitiinwa A, Lee KJ, Walker AS, Maganda A, Doerholt K, Kitaka SB, Asiimwe A, Judd A, **Musoke P**, Gibb DM; Collaborative HIV Paediatric Study (CHIPS) Steering Committee; Mulago Cohort Team. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. *J Acquir Immune Defic Syndr*. 2008 Dec 1;49(4):384-92.
 44. **Musoke P**, Barlow-Mosha L, Bagenda D et al. Response to Antiretroviral Therapy in HIV-infected Ugandan Children Exposed and Not Exposed to Single-Dose Nevirapine at Birth. *J Acquir Immune Defic Syndr* 2009 Dec 15 ;52(5): 560-568.
 45. Onyango-Makumbi C, Bagenda D, Mwatha A, Omer S, **Musoke P** et al. Early Weaning of HIV-Exposed Uninfected Infants and Risk of Serious Gastroenteritis: Findings from Two Perinatal HIV Prevention Trials in Kampala, Uganda. *J Acquir Immune Defic Syndr* 2010 Jan 1;53(1):20-27.
 46. **Musoke P**, Mudioppe P, Barlow-Mosha L, et al. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. *BMC Pediatrics* 2010,10.56.1-11
 47. Lubega I, Fowler MG, **Musoke P** et al. Considerations in Using US-Based Laboratory Toxicity Tables to Evaluate Laboratory Toxicities Among Healthy Malawian and Ugandan Infants. *J Acquir Immune Defic Syndr*. 2010 September 1; 55(1): 58–64
 48. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Mutsawashe Bwakura-D, Chi, BH, **Musoke P**, et al. Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure. *N Engl J Med*. 2010 October 14; 363(16): 1510–1520.

49. Imani PD, **Musoke P**, Byarugaba J, Tumwine JK. Human immunodeficiency virus infection and cerebral malaria in children in Uganda: a case-control study. *BMC Pediatrics* 2011,11:5. 2-8.
50. Toro PL, Katyal M, Carter RJ, Myer L, El-Sadr WM, Nash D, Abrams EJ; MTCT-Plus Initiative. Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. *AIDS*. 2010 Feb 20;24(4):515-24.
51. Towler WI, Barlow-Mosha L, Church JD, Bagenda D, Ajuna P, Mubiru M, **Musoke P**, Eshleman SH. Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. *AIDS Res Hum Retroviruses*. 2010;26(5):563-8.
52. Lubega I, Fowler MG, **Musoke P** et al. Considerations in Using US-Based Laboratory Toxicity Tables to Evaluate Laboratory Toxicities Among Healthy Malawian and Ugandan Infants. *J Acquir Immune Defic Syndr*. 2010 September 1; 55(1): 58–64.
53. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Mutsawashe Bwakura-D, Chi, BH, **Musoke P**, et al. Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure. *N Engl J Med*. 2010 October 14; 363(16): 1510–1520.
54. Church JD, Huang W, Mwatha A, **Musoke P** et al. Analysis of HIV tropism in Ugandan infants. *Curr HIV Res*. 2010 Oct;8(7):498-503.
55. Laeyendecker O, Church JD, Oliver AE, Mwatha A, Owen SM, Donnell D, Brookmeyer R, **Musoke P** et al. Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay. *PLoS One*. 2010 Oct 11;5(10):e13259.
56. Musiime V, Kendall L, Bakeera-Kitaka S, Snowden WB, Odongo F, Thomason M, **Musoke P**, et al. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. *Antivir Ther*. 2010;15(8):1115-24.
57. Imani PD, **Musoke P**, Byarugaba J, Tumwine JK. Human immunodeficiency virus infection and cerebral malaria in children in Uganda: a case-control study. *BMC Pediatrics* 2011,11:5. 2-8
58. Namukwaya Z, Mudiope P, Kekitiinwa A, **Musoke P**, Matovu J, Kayma S, Salmond W, Bitarakwate E, Mubiru M, Maganda A, Galla M, Byamugisha J, Fowler MG. The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 2007 to May 2009. *J Acquir Immune Defic Syndr*. 2011 Jan;56(1):69-75.
59. James MM, Wang J, **Musoke P**, et al. Association of HIV Diversity and Survival in HIV infected Ugandan Infants. *PLoS One*. 2011 Apr 14;6(4): e18642
60. Jao J, Lo W, Toro PL, Wyatt C, Palmer D, Abrams EJ, Carter RJ; MTCT-Plus Initiative Factors associated with decreased kidney function in HIV-infected adults enrolled in the MTCT-Plus Initiative in sub-Saharan Africa. *J Acquir Immune Defic Syndr*. 2011 May;57(1):40-5.
61. Nahiryia-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P, Mugenyi P, Kekitiinwa A, Bwakura-Dangarembizi MF, Crawley J; ARROW Trial

- Team. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. *Pediatr Infect Dis J*. 2011 Jun;30(6):535-7.
62. Buregyeya E, Kulane A, Colebunders R, Wajja A, Kiguli J, Mayanja H, **Musoke P**, Pariyo G, Mitchell EM. Tuberculosis knowledge, attitudes and health-seeking behaviour in rural Uganda. *Int J Tuberc Lung Dis*. 2011 Jul;15(7):938-42.
63. **Musoke PM**, Fergusson P. Severe malnutrition and metabolic complications of HIV-infected children in the antiretroviral era: clinical care and management in resource-limited settings. *Am J Clin Nutr*. 2011 Dec; 94(6):1716S-1720S.
64. Fillekes Q, Natukunda E, Balungi J, Kendall L, Bwakura-Dangarembizi M, Keishanyu R, Ferrier A, Lutakome J, Gibb DM, Burger DM, Walker AS; ARROW Trial Team. Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. *J Acquir Immune Defic Syndr*. 2011 Dec 1;58(4):392-8.
65. Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K, **Musoke P**, et al Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. *Lancet* 2012 Jan 21; 379(9812):221-8
66. Aizire J, Fowler MG, Wang J, Shetty AK, Stranix-Chibanda L, Kamateeka M, Brown ER, Bolton SG, **Musoke PM**, Coovadia H. Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. *AIDS*. 2012 Jan 28;26(3):325-33.
67. Tukei VJ, Asiimwe A, Maganda A, Atugonza R, Sebuliba I, Bakeera-Kitaka S, **Musoke P**, et al. Safety and Tolerability of Antiretroviral Therapy Among HIV-Infected Children And Adolescents In UGANDA. *J Acquir Immune Defic Syndr*. 2012; Mar 1;59(3):274-80.
68. Omer SB; Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. Six Week Extended Dose Nevirapine (SWEN) Study Team. *AIDS*. 2011 Mar 27;25(6):767-76.
69. Onyango-Makumbi C, Omer SB, Mubiru M, Moulton LH, Nakabiito C, **Musoke P**, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda. *J Acquir Immune Defic Syndr*. 2011 Dec 1;58(4):399-407.
70. Bagenda A, Barlow-Mosha L, Bagenda D, Sakwa R, Fowler MG, **Musoke PM**. Adherence to tablet and liquid formulations of antiretroviral medication for paediatric HIV treatment at an urban clinic in Uganda. *Ann Trop Paediatr*. 2011;31(3):235-45.
71. Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K, **Musoke P**, et al Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. *Lancet* 2012; 379(9812):221-8
72. Tukei VJ, Asiimwe A, Maganda A, Atugonza R, Sebuliba I, Bakeera-Kitaka S, **Musoke P**, Kalyesubula I, Kekitiinwa A. Safety and Tolerability of Antiretroviral Therapy Among HIV-Infected Children And Adolescents In UGANDA. *J Acquir Immune Defic Syndr*. 2012; 59 (3):274-80.

73. Aizire J, Fowler MG, Wang J, Shetty AK, Stranix-Chibanda L, Kamateeka M, Brown ER, Bolton SG, **Musoke PM**, Coovadia H. Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. *AIDS*. 2012; 26(3):325-33.
74. Barlow-Mosha L, Bagenda D, Mudiope P, Mubiru M, Butler L, Fowler M, **Musoke P**. The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children. *Afr Health Sci*. 2012 Sep;12(3):249-58.
75. James MM, Wang L, Donnell D, Cousins MM, Barlow-Mosha L, Fogel JM, Towler WI, Agwu AL, Bagenda D, Mubiru M, Musoke P, Eshleman SH. Use of a high resolution melting assay to analyze HIV diversity in HIV-infected Ugandan children. *Pediatr Infect Dis J*. 2012 Nov;31(11):e222-8.
76. Kintu K, Andrew P, Musoke P, Richardson P, Asiimwe-Kateera B, Nakyanzi T, Wang L, Fowler MG, Emel L, Ou SS, Baglyos L, Gurunathan S, Zwierski S, Jackson JB, Guay L. Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIV-exposed Infants in Uganda: Results from the First HIV Vaccine Trial in Infants in Africa. *J Acquir Immune Defic Syndr*. 2012 Dec 6.
77. Nantongo JM, Wobudeya E, Mupere E, Joloba M, Ssengooba W, Kisembo HN, Lubega IR, **Musoke PM**. High incidence of pulmonary tuberculosis in children admitted with severe pneumonia in Uganda. *BMC Pediatr*. 2013 Jan 31;13(1):16.
78. Asiimwe BB, Bagyenzi GB, Ssengooba W, Mumbowa F, Mboowa G, Wajja A, Mayanja-Kiiza H, **Musoke PM**, Wobudeya E, Kallenius G, Joloba ML. Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda. *BMC Infect Dis*. 2013 Feb 18;13(1):88.
79. Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R, Prendergast AJ, Lubwama S, Robertson V, Hughes P, Nathoo K, Munderi P, Klein N, **Musoke P**, Gibb DM. Bacteremia, Causative Agents and Antimicrobial Susceptibility among HIV-1 Infected Children on Antiretroviral Therapy in Uganda and Zimbabwe. *Pediatr Infect Dis J*. 2013 Feb 12.
80. Mudiope PK, Kim S, Wabwire D, Nyende L, Bagenda D, Mubiru M, Mulira R, Elbireer S, Namukwaya Z, Fowler MG, **Musoke P**. Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine. *Trop Med Int Health*. 2013 Mar;18(3):344-51.
81. Barlow-Mosha L, Eckard AR, McComsey GA, **Musoke PM**. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. *J Int AIDS Soc*. 2013 Jun 18;16:18600.
82. Kiweewa FM, Wabwire D, Nakibuuka J, Mubiru M, Bagenda D, **Musoke P**, Fowler MG, Antelman G. Non-inferiority of a task-shifting HIV care and treatment model using peer counselors and nurses among Ugandan women initiated on ART: evidence from a randomized trial. *J Acquir Immune Defic Syndr*. 2013 Aug 1;63(4):e125-32.
83. Waako J, Verver S, Wajja A, Ssengooba W, Joloba ML, Colebunders R, **Musoke P**, Mayanja-Kizza H. Burden of tuberculosis disease among adolescents in a rural cohort in Eastern Uganda. *BMC Infect Dis*. 2011 Jul 26;13(1):349.
84. Kaleebu P, Njai HF, Wang L, Jones N, Ssewanyana I, Richardson P, Kintu K, Emel L, **Musoke P**, Fowler MG, Ou SS, Jackson JB, Guay L, Andrew P, Baglyos L, Cao H;HPTN 027 protocol team. Immunogenicity of ALVAC-HIV vCP1521 in infants of

- HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. *J Acquir Immune Defic Syndr*. 2014 Mar 1;65(3):268-77.
85. Owor M, Mwatha A, Donnell D, Musoke P, Mmiro F, Allen M, Jackson JB, Fowler MG, Guay LA. Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival. *J Acquir Immune Defic Syndr*. 2013 15;64(5):464-71.
 86. Lutwama F, Kagina BM, Wajja A, Waiswa F, Mansoor N, Kirimunda S, Hughes EJ, Kiwanuka N, Joloba ML, Musoke P, Scriba TJ, Mayanja-Kizza H, Day CL, Hanekom WA. Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants. *J Infect Dis*. 2014 Mar;209(6):887-97.
 87. Fowler MG, Coovadia H, Herron CM, Maldonado Y, Chipato T, Moodley D, Musoke P, Aizire J, Manji K, Stranix-Chibanda L, Fawzi W, Chetty V, Msweli L, Kisenge R, Brown E, Mwatha A, Eshleman SH, Richardson P, Allen M, George K, Andrew P, Zwierski S, Mofenson LM, Jackson JB; HPTN 046 Protocol Team. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. *J Acquir Immune Defic Syndr*. 2014 Mar 1;65(3):366-74.
 88. Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, Nahirya Ntege P, Gibb DM, Thiebaut R, Walker AS, Klein N, Callard R; ARROW Trial Team. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modeling study. *PLoS Med*. 2013 Oct;10(10):e1001542.
 89. Nabongo P, Verver S, Nangobi E, Mutunzi R, Wajja A, Mayanja-Kizza H, Kadobera D, Galiwango E, Colebunders R, **Musoke P**. Two year mortality and associated factors in a cohort of children from rural Uganda. *BMC Public Health*. 2014 Apr 5;14(1):314.
 90. Massavon W, Barlow-Mosha L, Mugenyi L, McFarland W, Gray G, Lundin R, Costenaro P, Nannyonga MM, Penazzato M, Bagenda D, Namisi CP, Wabwire D, Mubiru M, Kironde S, Bilardi D, Mazza A, Fowler MG, **Musoke P**, Giaquinto C. Factors Determining Survival and Retention among HIV-Infected Children and Adolescents in a Community Home-Based Care and a Facility-Based Family-Centred Approach in Kampala, Uganda: A Cohort Study. *ISRN AIDS*. 2014 Apr 1;2014: 852489.
 91. Fillekes Q, Kendall L, Kitaka S, Mugenyi P, **Musoke P**, Ndigendawani M, Bwakura- Dangarembizi, Gibb DM, Burger D, Walker AS; ARROW Trial Team. Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. *Pediatr Infect Dis J*. 2014 May;33(5):495-8.
 92. Naranbhai V, Moodley D, Chipato T, Stranix-Chibanda L, Nakabaiito C, Kamateeka M, **Musoke P**, Manji K, George K, Emel LM, Richardson P, Andrew P, Fowler M, Fletcher H, McShane H, Coovadia HM, Hill AV; HPTN 046 Protocol Team. The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women. *J Acquir Immune Defic Syndr*. 2014 Dec 15;67(5):573-5.

93. Ssengooba W, Gelderbloem SJ, Mboowa G, Wajja A, Namaganda C, **Musoke P**, Mayanja-Kizza H, Joloba ML. Feasibility of establishing a biosafety level 3 tuberculosis culture laboratory of acceptable quality standards in a resource-limited setting: an experience from Uganda. *Health Res Policy Syst.* 2015 Jan 15;13:4.
94. Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. *Pediatr Infect Dis J.* 2015 Feb;34 (2)
95. Abdallah Y, Kaddu-Mulindwa D, Nankunda J, **Musoke PM**. Prevalence and immediate outcome of candida colonized preterm neonates admitted to Special Care Unit of Mulago Hospital, Kampala Uganda. *Afr Health Sci.* 2015 Mar;15(1):197-205
96. Pertussis prevalence and its determinants among children with persistent cough in urban Uganda. Kayina V, Kyobe S, Katabazi FA, Kigozi E, Okee M, Odongkara B, Babikako HM, Whalen CC, Joloba ML, **Musoke PM**, Mupere E. *PLoS One.* 2015 Apr 15;10(4) .
97. Namukwaya Z, Barlow-Mosha L, Mudiope P, Kekitiinwa A, Matovu JN, Musingye E, Ssebagala JN, Nakyanzi T, Abwooli JJ, Mirembe D, Etima J, Bitarakwate E, Fowler MG, **Musoke PM**; Peer-senga study Group at Mulago, Mengo, Rubaga and Mpigi Health Units.. Use of peers, community lay persons and Village Health Team (VHT) members improves six-week postnatal clinic (PNC) follow-up and Early Infant HIV Diagnosis (EID) in urban and rural health units in Uganda: A one-year implementation study. *BMC Health Serv Res.* 2015 Dec 15;15:555.
98. Buregyeya E, Kulane A, Kiguli J, **Musoke P**, Mayanja H, Mitchell EM. Motivations and concerns about adolescent tuberculosis vaccine trial participation in rural Uganda: a qualitative study. *Pan Afr Med J.* 2015 Sep 30;22:76.
99. Amongin D, Nakimuli A, Busingye R, Mubiru M, **Musoke P**, Mutyaba T. Effect of subsequent pregnancies on HIV disease progression among women in the Mulago Hospital MTCT-Plus program in Uganda. *Int J Gynaecol Obstet.* 2016 Mar;132(3):347-52.
100. Mumpe-Mwanja D, Verver S, Yeka A, Etwom A, Waako J, Ssengooba W, Matovu JK, Wanyenze RK, **Musoke P**, Mayanja-Kizza H. Prevalence and risk factors of latent Tuberculosis among adolescents in rural Eastern Uganda. *Afr Health Sci.* 2015 Sep;15(3):851-60.
101. John CC, Ayodo G, **Musoke P**. Successful Global Health Research Partnerships: What Makes Them Work? *Am J Trop Med Hyg.* 2016 Jan;94(1):5-7.
102. Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulosom H, Hunter P, **Musoke P**, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team.. Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy. *J Infect Dis.* 2016 Jul 15;214(2):226-36.
103. Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugenyi P, **Musoke P**, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team..

- Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. *BMC Med.* 2016 Mar 23;14:50.
104. Hobbs CV, Gabriel EE, Kamthunzi P, Tegha G, Tauzie J, Petzold E, Barlow-Mosha L, Chi BH, Li Y, Ilmet T, Kirmse B, Neal J, Parikh S, Deygoo N, Jean Philippe P, Mofenson L, Prescott W, Chen J, **Musoke P**, Palumbo P, Duffy PE, Borkowsky W;P1068s Study Team.. Malaria in HIV-Infected Children Receiving HIVProtease-Inhibitor- Compared with Non-Nucleoside Reverse TranscriptaseInhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060. *PLoS One.* 2016 Dec 9;11(12):e0165140.
 105. Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, **Musoke P**, Siberry G, Penazzato M. Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation. *J Int AIDS Soc.* 2017 Jun 27;20(1):21552.
 106. Nkwata AK, Zalwango SK, Kizza FN, Sekandi JN, Mutanga J, Zhang M, **Musoke PM**, Ezeamama AE. Quality of life among perinatally HIV-affected and HIV-unaffected school-aged and adolescent Ugandan children: a multi-dimensional assessment of wellbeing in the post-HAART era. *Qual Life Res.* 2017 Sep;26(9):2397-2408.
 107. Steenhoff AP, Crouse HL, Lukolyo H, Larson CP, Howard C, Mazhani L, Pak-Gorstein S, Niescierenko ML, **Musoke P**, Marshall R, Soto MA, Butteris SM, Batra M; GH Task Force of the American Board of Pediatrics. Partnerships for Global Child Health. *Pediatrics.* 2017 Oct;140(4).
 108. Voronin Y, Jani I, Graham BS, Cunningham CK, Mofenson LM, **Musoke PM**, Permar SR, Scarlatti G. Recent progress in immune-based interventions to prevent HIV-1 transmission to children. *J Int AIDS Soc.* 2017 Dec;20(4).
 109. Szubert AJ, Prendergast AJ, Spyer MJ, Musiime V, **Musoke P**, Bwakura-Dangarembizi M, Nahiryia-Ntege P, Thomason MJ, Ndashimye E, Nkanya I, Senfuma O, Mudenge B, Klein N, Gibb DM, Walker AS; ARROW Trial Team. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial. *PLoS Med.* 2017 Nov 14;14(11).
 110. **Musoke P**, Namukwaya Z, Barlow Mosha L. Prevention and treatment of Pediatric HIV infection. *Current Tropical Medical Report* 2018.
 111. Yakah W, Fenton JI, Sikorskii A, Zalwango SK, Tuke R, **Musoke P**, Boivin MJ, Giordani B, Ezeamama AE. Serum Vitamin D is Differentially Associated with socioemotional Adjustment in Early School-Aged Ugandan Children According to Perinatal HIV Status and In Utero/Peripartum Antiretroviral Exposure History. *Nutrients.* 2019 Jul 12;11(7). Webster KD, de Bruyn MM, Zalwango SK, Sikorskii A, Barkin JL, Familiar-Lopez I, **Musoke P**, Giordani B, Boivin MJ, Ezeamama AE. Caregiver socioemotional health as a determinant of child well-being in school-aged and adolescent Ugandan children with and without perinatal HIV exposure. *Trop Med Int Health.* 2019 May;24(5):608.
 112. Jain R, Azeamama AE, Sikorskii A, Yakah W, Zalwango S, **Musoke P**, Boivin MJ, Fenton JI. Serum n-6 Fatty Acids are Positively Associated with Growth in 6-to-10-

- Year Old Ugandan Children Regardless of HIV Status-A Cross-Sectional Study. *Nutrients*. 2019 Jun 4;11(6).
113. Bakeera-Kitaka S, Smekens T, Jespers V, Wobudeya E, Loos J, Colebunders R, Adipo D, Kekitiinwa A, **Musoke P**, Buve A, Nöstlinger C. Factors Influencing the Risk of Becoming Sexually Active Among HIV Infected Adolescents in Kampala and Kisumu, East Africa. *AIDS Behav*. 2019 Jun;23(6):1375-1386.
 114. Nakatudde I, Rujumba J, Namiro F, Sam A, Mugalu J, **Musoke P**. Vaccination timeliness and associated factors among preterm infants at a tertiary hospital in Uganda. *PLoS One*. 2019 Sep 6;14(9):e0221902.
 115. Mumpe-Mwanja D, Barlow-Mosha L, Williamson D, Valencia D, Serunjogi R, Kakande A, Namale-Matovu J, Nankunda J, Birabwa-Male D, Okwero MA, Nsungwa-Sabiiti J, **Musoke P**. A hospital-based birth defects surveillance system in Kampala, Uganda. *BMC Pregnancy Childbirth*. 2019 Oct22;19(1):372.
 116. Namale-Matovu J, Barlow-Mosha L, Mumpe-Mwanja D, et al. Overcoming staffing challenges when implementing a birth defects surveillance system: a Ugandan experience. *Journal of Global Health Reports*. 2020;4:e2020022.
 117. Nalwanga D, Musiime V, Kizito S, et al. Mortality among children under five years admitted for routine care of severe acute malnutrition: a prospective cohort study from Kampala, Uganda. *BMC Pediatr*. 2020;20(1):182.
 118. King R, Matovu JN, Rujumba J, et al. PMTCT Option B+ 2012 to 2018 - Taking stock: barriers and strategies to improve adherence to Option B+ in urban and rural Uganda. *Afr J AIDS Res*. 2020;19(2):135-146.